Theseus Pharmaceuticals Inc (DELISTED) (THRX:DL)
4.06
0.00 (0.00%)
USD |
NASDAQ |
Feb 23, 16:00
Theseus Pharmaceuticals SG&A Expense (Quarterly): 4.884M for Sept. 30, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 4.884M |
| June 30, 2023 | 4.668M |
| March 31, 2023 | 4.654M |
| December 31, 2022 | 5.096M |
| September 30, 2022 | 4.525M |
| June 30, 2022 | 4.736M |
| March 31, 2022 | 4.031M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.637M |
| September 30, 2021 | 2.378M |
| June 30, 2021 | 2.329M |
| March 31, 2021 | 0.664M |
| December 31, 2020 | 0.40M |
| September 30, 2020 | 0.154M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.154M
Minimum
Sep 2020
5.096M
Maximum
Dec 2022
3.243M
Average
4.031M
Median
Mar 2022
SG&A Expense (Quarterly) Benchmarks
| Karuna Therapeutics Inc (DELISTED) | 47.39M |
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |
| iBio Inc | 2.961M |
| Theriva Biologics Inc | 1.933M |